ERBB2 and neoplasm: Our findings of elevated IL-4 levels in non-responders to neoadjuvant chemotherapy in LuminalB/HER2 + breast cancer align with previous research demonstrating IL-4’s role in promoting tumor survival and chemotherapy resistance.